Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 6/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25172149 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL31079721 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL5987271 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL31079904 | 1.00 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL5987162 | 0.98 | HTR1B (0.65) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL5988009 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL29528156 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL24429342 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL25237253 | 0.86 | HTR1B (0.67) | HTR1BHTR2AHTR2CHTR2BPNMT | |
| SCHEMBL13034824 | 0.86 | HTR1B (0.71) | HTR1BHTR2AHTR2CHTR2BCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727538-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4673125-A1 | R-MDMA FOR TREATMENT OF PAIN | Mind Medicine, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615585-A1 | METHODS OF USING TRAZODONE TO REVERSE THE EFFECTS OF 5-HT2A RECEPTOR AGONISTS | Gilgamesh Pharmaceuticals, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| US-20240423950-A1 | 5-MAPB OR 6-APB FOR USE IN DRUG-ASSISTED PSYCHOTHERAPY | Clearmind Medicine Inc. (IL) | 2024-12-26 | — | — | US | claimed |
| WO-2024259343-A2 | NEW FORMULATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2024-12-19 | — | — | WO | claimed |
| WO-2024226995-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | YALE UNIVERSITY (US) | 2024-10-31 | — | — | WO | claimed |
| EP-4444283-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | Tactogen Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| US-20230233688-A1 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | Mind Medicine, Inc. (US) | 2023-07-27 | — | — | US | claimed |
| US-20230218570-A1 | Methods and Compositions for Treating Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder | LOBE SCIENCES LTD. (CA) | 2023-07-13 | — | — | US | claimed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023057953-A1 | 5-MAPB OR 6-APB FOR USE IN DRUG-ASSISTED PSYCHOTHERAPY | Clearmind Medicine Inc. (IL) | 2023-04-13 | — | — | WO | claimed |
| US-20230066171-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2023-03-02 | — | — | US | claimed |
| WO-2023028022-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | claimed |
| WO-2022256720-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | ARCADIA MEDICINE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| WO-2022106947-A1 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | LIECHTI MATTHIAS EMANUEL (CH) | 2022-05-27 | — | — | WO | claimed |
| US-20220151986-A1 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | Mind Medicine, Inc. (US) | 2022-05-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR1B 10/4885HTR2A 14/4885HTR2C 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.